Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cefepime-taniborbactam vs Meropenem in Adults With VABP or vHABP
NCT06168734Phase 3Withdrawn
- Sponsor
- Venatorx Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Jun 2027
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
01
Overview
A Phase 3 trial of cefepime + taniborbactam in ventilator-associated pneumonia (VAP), sponsored by Venatorx Pharmaceuticals. Planned start Jun 2025; status: withdrawn.
02
Drugs
cefepime + taniborbactam
03
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT06168734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06168734.